Financial News Search | Sharemaestro Newsreel

10:19 3 Aug 2026

marketscreener.com Deals and strategy Main company 🇧🇷 Brazil

AstraZeneca shares slide 7% after reports of Bristol Myers talks

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

09:09 3 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:14 3 Aug 2026

uk.finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. The two pharmaceutical firms have held discussions over a potential tie-up in recent months, the Financial Times …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

07:01 3 Aug 2026

nasdaq.com Earnings Main company 🇧🇷 Brazil

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both AstraZeneca and Bristol …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

22:14 2 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report. A combined entity would carry a value of nearly $400 billion, which …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

21:20 2 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

AstraZeneca plots £300bn tie-up with US rival

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company's ties to the UK. Britain's second-most valuable company has held talks with Bristol Myers Squibb in recent months about a …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

07:30 31 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:09 29 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AstraZeneca (LSE:AZN) Stock In Focus After Sone Ve Win And Mixed Ultomiris Data

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AstraZeneca reported positive Phase III results for sonesitatug vedotin in Claudin 18.2-positive advanced gastric …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:09 29 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Does AstraZeneca (LSE:AZN) Have More Value Than The Market Prices In?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca stock has delivered a 73.3% total return over the past five years, and both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

14:32 28 Jul 2026

finance.yahoo.com Analyst action Main company 🇧🇷 Brazil

AstraZeneca's drug pipeine is splitting opinion among City analysts

AstraZeneca's drug pipeine is splitting opinion among City analysts Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

10:13 28 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS

For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

18:54 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure

AstraZeneca AZN reported second-quarter 2026 core earnings of $2.63 per share, which beat the Zacks Consensus Estimate of $2.50. Earnings rose 21% year over year on a reported basis and 18% at constant exchange rate (CER). Total revenues of $15.38 billion rose 6% on …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

17:03 27 Jul 2026

seekingalpha.com Market update Main company 🇧🇷 Brazil

Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a rare disorder leading to blood clots and harm to small blood vessels, has led shares of Omeros …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

16:58 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Astrazeneca (AZN) reported $15.38 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.4%. EPS of $2.63 for the same period compares to $2.18 a year ago. The reported revenue represents a surprise of +0.48% over the Zacks Consensus …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

14:02 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Astrazeneca Q2 Earnings Call Highlights

Key Points Interested in Astrazeneca Plc? Here are five stocks we like better. Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11% excluding generic-competition effects, while core EPS rose 11%. The company maintained its full-year outlook and reaffirmed …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:56 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AstraZeneca Q2 2026 earnings beat on cancer drug sales

AstraZeneca reported second-quarter results on Monday that topped profit expectations, with the Anglo-Swedish pharmaceutical company holding its 2026 guidance and $80 billion annual revenue target for 2030. Core earnings per share reached $2.63 for the three months ended June 30, a gain of 18% …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:52 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Earnings live: LVMH sales grow as US luxury shoppers boost results

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:52 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Earnings live: AstraZeneca stock rises to kick off a busy earnings week

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:29 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AstraZeneca profit rises on strong cancer drug sales

AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs. Profit after tax climbed more than two percent …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:05 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca's wholly owned …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

12:00 27 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 CAMBRIDGE, England, July 27, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

10:02 27 Jul 2026

uk.finance.yahoo.com Macro sensitivity Main company 🇧🇷 Brazil

AstraZeneca sales rise as demand for cancer treatments grow

AstraZeneca has revealed that demand for its range of cancer treatments buoyed sales this year as the drugs giant increased spending on new research. The Cambridge-based company said sales growth within its oncology and rare disease divisions helped deliver a boost. It reported total …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

09:19 27 Jul 2026

nasdaq.com Earnings Main company 🇧🇷 Brazil

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:57 27 Jul 2026

seekingalpha.com Earnings Main company 🇧🇷 Brazil

AstraZeneca PLC declares $1.06 interim dividend

* AstraZeneca PLC (AZN [https://seekingalpha.com/symbol/AZN]) declares a $1.06/share interim dividend [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html]. * Payable Sept. 8; for shareholders of record Aug. 7; ex-div Aug. 7. * Looking ahead for FY 2026, the company intends to increase its total annual dividend payout to $3.30 per share. …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:30 27 Jul 2026

seekingalpha.com Earnings Main company 🇧🇷 Brazil

Earnings Snapshot: AstraZeneca reports Q2 earnings beat, raises interim dividend, and reaffirms FY26 guidance

[Seeking Alpha] Seeking Alpha (Seeking Alpha) MORE ON ASTRAZENECA PLC * AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback [https://seekingalpha.com/article/4922348-astrazeneca-oncology-engine-keeps-running-despite-wainua-setback] * AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic [https://seekingalpha.com/article/4921003-astrazeneca-and-ionis-pharma-rocked-by-heart-disease-fail-why-you-shouldnt-panic] * AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:15 27 Jul 2026

seekingalpha.com Earnings Main company 🇧🇷 Brazil

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

* AstraZeneca PLC press release [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html] (AZN [https://seekingalpha.com/symbol/AZN]): Q2 Non-GAAP EPS of $2.63 beats by $1.36. * Revenue of $15.38B (+6.4% Y/Y) misses by $50M. * Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK). * FY2026 Revenue estimated growth …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

07:27 27 Jul 2026

nasdaq.com Earnings Main company 🇧🇷 Brazil

AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues. Looking ahead for fiscal 2026, AstraZeneca continues to expect total revenue to increase by a mid-to-high single-digit percentage, and core earnings per share …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

16:27 26 Jul 2026

nasdaq.com Earnings Main company 🇧🇷 Brazil

AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?

(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026. AstraZeneca, as a biopharmaceutical company, offers multiple products for oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and therapies for rare diseases. AstraZeneca's blockbuster …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

22:11 24 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

AstraZeneca (LSE:AZN) Wins EU Approval For Etcamah In Advanced Breast Cancer

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, HER2-negative advanced breast cancer. The decision is based on Phase III SERENA-6 trial …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

16:30 24 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer

AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer. The EC approved Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

08:16 24 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

07:16 24 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

04:16 24 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story

Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

10:13 23 Jul 2026

nasdaq.com Regulatory and legal Main company 🇧🇷 Brazil

AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer

(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union or EU for the treatment of adult patients for an advanced breast …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

14:15 22 Jul 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.50 per share in its upcoming report, which indicates a year-over-year increase of 14.7%. Revenues are expected to be $15.31 billion, up 5.9% from the year-ago quarter. The current level reflects a downward …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4%

76 matching headlines